Phathom Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Phathom Pharmaceuticals's estimated annual revenue is currently $14.9M per year.
- Phathom Pharmaceuticals's estimated revenue per employee is $40,325
- Phathom Pharmaceuticals's total funding is $340M.
- Phathom Pharmaceuticals's current valuation is $479.7M. (January 2022)
Employee Data
- Phathom Pharmaceuticals has 369 Employees.
- Phathom Pharmaceuticals grew their employee count by 200% last year.
Phathom Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 14 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 22 | -8% | N/A | N/A |
#10 | $9.6M | 53 | 4% | N/A | N/A |
What Is Phathom Pharmaceuticals?
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement ᅢᄁ¬ツᆲ¬タン elements that are key to our success.
keywords:N/A$340M
Total Funding
369
Number of Employees
$14.9M
Revenue (est)
200%
Employee Growth %
$479.7M
Valuation
N/A
Accelerator
Phathom Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Regional Sales Manager | Reveal Email/Phone |
2 | Regional Sales Manager | Reveal Email/Phone |
3 | Senior Director, GI National Accounts | Reveal Email/Phone |
4 | Regional Sales Manager | Reveal Email/Phone |
5 | Senior Director, Quality & Compliance | Reveal Email/Phone |
6 | Senior Director, National Accounts | Reveal Email/Phone |
7 | VP, Head - Medical Affairs | Reveal Email/Phone |
8 | VP Manufacturing and Supply Chain | Reveal Email/Phone |
9 | Director, Supply Chain | Reveal Email/Phone |
10 | Associate Director R&D Finance | Reveal Email/Phone |
Phathom Pharmaceuticals News
At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc. PHAT-0.61%+ Free Alerts. says that licensor Takeda Pharmaceutical Co Ltd.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals, Inc. reported it has obtained a $200 million term loan facility from Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capital further strengthens Phathoms balance sheet in advanc ...
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan f ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $93.7M | 391 | 2% | N/A |
#2 | $35M | 400 | N/A | N/A |
#3 | $173.8M | 421 | 8% | $1.1B |
#4 | $115.4M | 491 | 4% | N/A |
#5 | $197.8M | 610 | 1% | N/A |